# Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

> **NCT02160223** · PHASE4 · COMPLETED · sponsor: **Diskapi Teaching and Research Hospital** · enrollment: 74 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT02160223
- **Lead sponsor:** Diskapi Teaching and Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2014-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160223, "Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02160223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*